Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2020-07-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Quarter 2 Update 4 pages 381.1KB
Interim / Quarterly Report Classification · 95% confidence The document is titled as an ASX Announcement and provides a quarterly activities and cash flow report for the quarter ended 30 June 2020. It includes operational highlights, cash reserves, net cash used, capital raising details, product launches, and updates on business operations. The content is comprehensive and includes substantive financial data and analysis for a period shorter than a full fiscal year, consistent with a quarterly report. It is not merely an announcement of a report or a certification, but contains actual financial and operational information. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2020
2020-07-27 English
Change of Director's Interest Notice 3 pages 216.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a director, including the number of shares held before and after the change, the nature of the interest, and the value/consideration. This is a clear report of personal share transactions by a company director. The document length is 3870 characters, which is consistent with a detailed director's dealing notice. There is no indication that this is an announcement of a report or a certification. Therefore, the document fits the definition of 'Director's Dealing' (DIRS).
2020-07-27 English
Appendix 2A 14 pages 216.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance of new shares, reasons for issuance, and compliance with ASX listing rules. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement related to capital changes. This fits the category of Share Issue/Capital Change (SHA). The document length is substantial and contains detailed information about the securities issuance, confirming it is not a mere announcement of a report but a formal filing for capital change.
2020-07-23 English
Change in substantial holding 3 pages 818.6KB
Regulatory Filings
2020-07-06 English
Becoming a substantial holder 4 pages 1.0MB
Regulatory Filings
2020-06-29 English
Results of Meeting 2 pages 121.0KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement dated 26 June 2020 reporting the results of an Annual General Meeting (AGM) of Lifespot Health Limited. It includes detailed voting results on various resolutions such as adoption of the remuneration report, re-election of a director, and share issues. The document references ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, which pertain to disclosure of meeting results. The content is focused on the official voting outcomes rather than the meeting materials or the full AGM report. The document length is 3457 characters, which is relatively short and consistent with a voting results announcement rather than a full AGM presentation or annual report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-06-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.